APA

Xing P., Mu Y., Wang Y., Hao X., Zhu Y., Hu X., Wang H., Liu P., Lin L., Wang Z. & Li J. (20190212). Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer. : Thoracic cancer.

Chicago

Xing Puyuan, Mu Yuxin, Wang Yan, Hao Xuezhi, Zhu Yixiang, Hu Xingsheng, Wang Hongyu, Liu Peng, Lin Lin, Wang Zhijie and Li Junling. 20190212. Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer. : Thoracic cancer.

Harvard

Xing P., Mu Y., Wang Y., Hao X., Zhu Y., Hu X., Wang H., Liu P., Lin L., Wang Z. and Li J. (20190212). Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer. : Thoracic cancer.

MLA

Xing Puyuan, Mu Yuxin, Wang Yan, Hao Xuezhi, Zhu Yixiang, Hu Xingsheng, Wang Hongyu, Liu Peng, Lin Lin, Wang Zhijie and Li Junling. Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer. : Thoracic cancer. 20190212.